Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)

NCT00817284 | Completed Phase 2

• 1 other identifier: BIBT-01
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 3

Brief Summary

Significant activity (radiographic response rates of approximately 60%) has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use of Irinotecan (CPT-11) and bevacizumab. The 6-month progression-free survival rate is 30% and median survival duration is 9 months. The current first line therapy of GBM patients following initial surgical resection/debulking is the concomitant use of cerebral radiotherapy and the orally available alkylating agent temozolomide, followed by temozolomide for 6 months post-radiotherapy. Considering the significant activity of the combination of Bevacizumab + irinotecan in patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is proposed that the combination of Bevacizumab + Temozolomide may also be an active regimen. Bevacizumab + Temozolomide display non-overlapping toxicity clinically and thus their combined use without significant dose-reductions seems rational. The toxicity from the combined use of the two drugs prior to radiotherapy, as well as the toxicity when administered together with radiotherapy, is evaluated. This study will try to identity whether Bevacizumab and Irinitecan or Bevacizumab and Temozolomide should be the experimental arm in future phase III comparison with standard care with concomitant Temozolomide and radiotherapy.

Conditions

Glioblastoma Multiforme

Keywords

Newly diagnosed patients with glioblastoma multiforme.; Performance status 0-2.

Outcome Measures

Primary Outcomes (1)

• Objective response rate according to McDonald criteria

  6 months

Secondary Outcomes (1)

• Progression-free survival

  6 months

Study Arms (2)

arm I

EXPERIMENTAL

Bevacizumab + Irinotecan and concomitant radiotherapy

Drug: bevacizumab and Irinotecan and radiotherapy

Arm II

EXPERIMENTAL

Bevacizumab and Temozolomide and concomitant radiotherapy

Drug: Bevacizumab and Temozolomide and radiotherapy

Interventions

bevacizumab and Irinotecan and radiotherapy DRUG

* Bevacizumab 10 mg/kg is administered on days 1 and 15. * Irinotecan: * Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED). * Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs. * During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy. Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.

arm I

Bevacizumab and Temozolomide and radiotherapy DRUG

Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy. Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy. After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made. Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.

Arm II

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed informed consent
• Histological verified primary glioblastoma multiforme
• No prior therapy for GBM, except for primary surgical resection or biopsy
• PS 0-2
• Age \> 18
• Expected survival \> 3 months
• Adequate liver, renal and bone-marrow function, determined as:
• Thrombocytes \> 100 x 109/liter
• Hemoglobin \>6.2 mmol/liter
• Leukocytes \> 3 x 109/liter
• Neutrophil granulocytes \> 1.5 x 109/liter
• ASAT and/or ALAT \< 3 x upper normal limit
• Bilirubin \< 1.5 x upper normal limit
• Serum-creatinin \< upper normal limit or glomerular filtration rate \>60 ml/min (corrected for age) determined by measurement of clearance of Cr-EDTA
• APTT \< upper normal limit

You may not qualify if:

• Previous therapy of GBM, including radiotherapy and the use of biological " targeted" drug, e.g. drugs targeted against the VEGF- or EGFR pathway
• Concurrent use of medication that can affect the interpretation of the results from the study, e.g. use of immunosuppressive drugs, except corticosteroids
• Conditions (medical, social or physical) that may compromise proper information and/or follow-up
• Other concurrent or previous cancer within 5 years, except adequately treated basal or planocellular skin cancer, or cervical carcinoma in situ
• Significant heart disease (according to the New York Heart Association class II or more severe), clinically significant arrhythmia or unstable angina pectoris/acute myocardial infarction within last 6 months
• Clinical significant peripheral arterial disease
• Known or suspected disorders of coagulation or concurrent therapy with ASA, NSAID or clopidogrel
• Major surgery, open biopsy or greater trauma, or expectations thereof, within 28 days prior to start of therapy
• Minor surgery or needle biopsy, or expectations thereof, within 7 days prior to start of therapy
• Known or suspected abdominal fistulas, gastrointestinal perforations or intra-abdominal abscesses within 6 months prior to start of therapy
• Chronic inflammatory intestinal disease and/or intestinal obstruction
• Known or active HIV or Hepatitis B/C infection
• Concurrent ongoing significant infection or diabetes mellitus not adequately controlled medically
• Clinically significant non-healing ulcers
• Active ventricular or duodenal ulcers within 6 months prior to start of therapy

Sponsors & Collaborators

• Ulrik Lassen: lead

Study Sites (3)

Århus Hospital

Aarhus, Denmark

Location

Rigshospitalet

Copenhagen, Denmark

Location

Odense Hospital

Odense, Denmark

Location

MeSH Terms

Conditions

Glioblastoma

Interventions

Bevacizumab; Irinotecan; Radiotherapy; Temozolomide

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Camptothecin; Alkaloids; Heterocyclic Compounds; Therapeutics; Dacarbazine; Triazenes; Organic Chemicals; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: MD., PH.D. Chief Physician, Phase I Unit

Study Record Dates

• First Submitted: December 8, 2008
• First Posted: January 6, 2009
• Study Start: November 1, 2008
• Primary Completion: November 1, 2011
• Study Completion: November 1, 2011
• Last Updated: November 30, 2011

Record last verified: 2011-11

Locations

DK (3)